NasdaqGS - Nasdaq Real Time Price USD

Repligen Corporation (RGEN)

Compare
139.04 -4.19 (-2.93%)
At close: 4:00 PM EDT
139.04 0.00 (0.00%)
After hours: 4:01 PM EDT
Loading Chart for RGEN
DELL
  • Previous Close 143.23
  • Open 142.00
  • Bid 138.71 x 100
  • Ask 139.20 x 100
  • Day's Range 138.67 - 143.40
  • 52 Week Range 110.45 - 211.13
  • Volume 359,418
  • Avg. Volume 838,282
  • Market Cap (intraday) 7.787B
  • Beta (5Y Monthly) 0.95
  • PE Ratio (TTM) --
  • EPS (TTM) -0.03
  • Earnings Date Oct 29, 2024 - Nov 4, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 193.32

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.

www.repligen.com

1,783

Full Time Employees

December 31

Fiscal Year Ends

Recent News: RGEN

View More

Performance Overview: RGEN

Trailing total returns as of 10/3/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

RGEN
22.67%
S&P 500
19.50%

1-Year Return

RGEN
10.27%
S&P 500
32.92%

3-Year Return

RGEN
50.63%
S&P 500
30.82%

5-Year Return

RGEN
88.30%
S&P 500
97.39%

Compare To: RGEN

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: RGEN

View More

Valuation Measures

Annual
As of 10/2/2024
  • Market Cap

    8.02B

  • Enterprise Value

    7.96B

  • Trailing P/E

    466.37

  • Forward P/E

    77.52

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    13.35

  • Price/Book (mrq)

    4.04

  • Enterprise Value/Revenue

    13.21

  • Enterprise Value/EBITDA

    86.52

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -0.32%

  • Return on Assets (ttm)

    0.19%

  • Return on Equity (ttm)

    -0.10%

  • Revenue (ttm)

    602.35M

  • Net Income Avi to Common (ttm)

    -1.9M

  • Diluted EPS (ttm)

    -0.03

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    809.15M

  • Total Debt/Equity (mrq)

    37.40%

  • Levered Free Cash Flow (ttm)

    120.45M

Research Analysis: RGEN

View More

Earnings Per Share

Consensus EPS
 

Revenue vs. Earnings

Revenue 154.07M
Earnings 3.32M
 

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell
 

Analyst Price Targets

160.00
193.32 Average
139.04 Current
225.00 High
 

Company Insights: RGEN

Research Reports: RGEN

View More
  • Repligen: Initiating Coverage With Narrow Moat Rating and $180 FVE; Shares Undervalued

    Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 54% of 2023 revenue, while chromatography, proteins, and process analytics were 20%, 16%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.

    Rating
    Price Target
     
  • What does Argus have to say about RGEN?

    REPLIGEN CORP has an Investment Rating of SELL; a target price of $120.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Low.

    Rating
    Price Target
     
  • Lowering target price to $118.00

    REPLIGEN CORP has an Investment Rating of SELL; a target price of $118.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Low.

    Rating
    Price Target
     
  • Raising target price to $120.00

    REPLIGEN CORP has an Investment Rating of SELL; a target price of $120.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Medium; and a Value Subrating of Low.

    Rating
    Price Target
     

People Also Watch